Everything below concerns lyophilized powder. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-06-29. Numbers and descriptions here follow the published literature rather than marketing material.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
The compound is most often distributed as a lyophilized powder, appearing white to off-white and forming a loose cake or fluffy solid. It is hygroscopic to some degree, so brief exposure to humid air can add water weight and complicate weighing. The peptide dissolves readily in water and in neutral aqueous buffers, and aqueous solubility is generally described as high, well above the concentrations used in typical assays. Some polar organic solvents are also usable, which matters when a concentrated stock is prepared before dilution into buffer.
Storage recommendations center on keeping the dry powder cold, dry, and dark. A freezer at -20 degrees Celsius or below is conventional, and desiccant is often included to limit moisture uptake. Once dissolved, the peptide is less stable, and solutions are typically kept frozen and thawed only once. Repeated freeze-thaw cycles are a common source of losses because they promote aggregation and adsorption to container surfaces. Working aliquots are therefore prepared in advance, and glass or low-binding plastic is usually preferred over ordinary laboratory plastic.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilised powder | Sealed vial; reconstituted before laboratory use |
| Appearance | White to off-white solid | Visual descriptor used on certificates of analysis |
| Solubility class | Water-soluble | Dissolves in water and aqueous buffers |
| Reported mass, fragment | Near 889 Da | Value depends on the stated sequence |
| Reported mass, parent protein | Near 4963 Da | 43-residue thymosin beta-4 |
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
== Inhibitors == Pepsin may be inhibited by high pH (see Activity and stability) or by inhibitor compounds. Pepstatin is a low molecular weight compound and potently inhibitor specific for acid proteases with an inhibitory dissociation constant (Ki) of about 10−10 M for pepsin. The statyl residue of pepstatin is thought to be responsible for pepstatin inhibition of pepsin; statine is a potential analog of the transition state for catalysis by pepsin and other acid proteases. Pepstatin does not covalently bind pepsin, and inhibition of pepsin by pepstatin is therefore reversible. 1-bis(diazoacetyl)-2-phenylethane reversibly inactivates pepsin at pH 5, a reaction which is accelerated by the presence of Cu(II). Porcine pepsin is inhibited by pepsin inhibitor-3 (PI-3) produced by the large roundworm of pig (Ascaris suum). PI-3 occupies the active site of pepsin using its N-terminal residues and thereby blocks substrate binding. Amino acid residues 1 - 3 (Gln-Phe-Leu) of mature PI-3 bind to P1' - P3' positions of pepsin. The N-terminus of PI-3 in the PI-3:pepsin complex is positioned by hydrogen bonds which form an eight-stranded β-sheet, where three strands are contributed by pepsin and five by PI-3. A product of protein digestion by pepsin inhibits the reaction. Sucralfate, a drug used to treat stomach ulcers and other pepsin-related conditions, also inhibits pepsin activity.
=== Non-tuberculous mycobacteria === Isoniazid may also be used off-label to treat nontuberculous mycobacterial pulmonary disease. Isoniazid was widely used in the treatment of Mycobacterium avium complex as part of a regimen including rifampicin and ethambutol. Evidence suggests that isoniazid prevents mycolic acid synthesis in M. avium complex as in M. tuberculosis and although this is not bactericidal to M. avium complex, it greatly potentiates the effect of rifampicin.
== Receptors == Relaxin interacts with the relaxin receptor LGR7 (RXFP1) and LGR8 (RXFP2), which belong to the G protein-coupled receptor superfamily. They contain a heptahelical transmembrane domain and a large glycosylated ectodomain, distantly related to the receptors for the glycoproteohormones, such as the LH-receptor or FSH-receptor. Relaxin receptors have been found in the heart, smooth muscle, the connective tissue, and central and autonomous nervous system.
Sources: en.wikipedia.org
==== Disorganized crime ==== The economist Peter Reuter has challenged the conventional framework of crime taking place in an organized manner with respect to drug trafficking. He argues that criminal organizations are unable to form monopolies and trend toward factionalism. Reuter and other skeptics have said that drug cartels and mafias are rhetorical constructs used by police and prosecutors to simplify a complex and heterogeneous criminal underworld that is in fact composed of smaller competing cliques and informal social networks.
"2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides". Arthritis & Rheumatism. 65 (1): 1–11. doi:10.1002/art.37715. PMID 23045170. Jennette, J. Charles (2013). "Overview of the 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides". Clinical and Experimental Nephrology. 17 (5): 603–606. doi:10.1007/s10157-013-0869-6. PMC 4029362. PMID 24072416. Xiao, Hong; Dairaghi, Daniel J.; Powers, Jay P.; Ertl, Linda S.; Baumgart, Trageen; Wang, Yu; Seitz, Lisa C.; Penfold, Mark E.T.; Gan, Lin; Hu, Peiqi; Lu, Bao; Gerard, Norma P.; Gerard, Craig; Schall, Thomas J.; Jaen, Juan C.; Falk, Ronald J.; Jennette, J. Charles (2014). "C5a Receptor (CD88) Blockade Protects against MPO-ANCA GN". Journal of the American Society of Nephrology. 25 (2): 225–231. doi:10.1681/ASN.2013020143. PMC 3904560. PMID 24179165. Jennette, J. Charles; Nachman, Patrick H. (2017). "ANCA Glomerulonephritis and Vasculitis". Clinical Journal of the American Society of Nephrology. 12 (10): 1680–1691. doi:10.2215/CJN.02500317. PMC 5628710. PMID 28842398. Haas, Mark; Seshan, Surya V.; Barisoni, Laura; Amann, Kerstin; Bajema, Ingeborg M.; Becker, Jan Ulrich; Joh, Kensuke; Ljubanovic, Danica; Roberts, Ian S.D.; Roelofs, Joris J.; Sethi, Sanjeev; Zeng, Caihong; Jennette, J. Charles (2020). "Consensus definitions for glomerular lesions by light and electron microscopy: Recommendations from a working group of the Renal Pathology Society". Kidney International. 98 (5): 1120–1134. doi:10.1016/j.kint.2020.08.006. PMID 32866505.
== Swedish Mass Spectrometry Society == The Swedish Mass Spectrometry Society recognizes distinguished contribution to Swedish mass spectrometry with its Gold Berzelius Medal and early career contribution with its Silver Berzelius Medal.
Sources: en.wikipedia.org
Internal waters: Waters landward of the baseline, over which the state has complete sovereignty: not even innocent passage is allowed without explicit permission from said state. Lakes and rivers are considered internal waters. Territorial sea: A state's territorial sea is a belt of coastal waters extending at most 22 kilometres from the baseline of a coastal state. If this overlaps with another state's territorial sea, the border is taken as the median line between the states' baselines, unless the states in question agree otherwise. A state can also choose to claim a smaller territorial sea. The territorial sea is regarded as the sovereign territory of the state. However, foreign ships (military and civilian) are allowed innocent passage through it, or transit passage for straits; this sovereignty also extends to the airspace over and seabed below. As a result of UNCLOS, states exercise a similar degree of control over their territorial sea as over land territory. They may thus utilise coast guard and naval patrols to enforce border control measures, provided they do not prevent innocent or transit passage. Contiguous zone: A state's contiguous zone is a band of water extending farther from the outer edge of the territorial sea to up to 44 kilometres (27 miles) from the baseline, within which a state can implement limited border control measures for the purpose of preventing or punishing "infringement of its customs, fiscal, immigration or sanitary laws and regulations within its territory or territorial sea".
=== Plants as bioreactors for vaccine production === The idea of vaccine production via transgenic plants was identified as early as 2003. Plants such as tobacco, potato, tomato, and banana can have genes inserted that cause them to produce vaccines usable for humans. In 2005, bananas were developed that produce a human vaccine against hepatitis B.
Reilly suggested to Ding at that time that they should focus the DIT for analysis in the high mass range where other instruments could not compete. However, work published by Ding and Shimadzu over the years following the 2001 meeting were focused on development of square wave driven DIT's in the conventional mass range of commercial instrumentation. During this time Reilly began developing digital waveforms to increase the mass range of quadrupole-based mass spectrometers and ion traps that operate with rectangular waveforms. Over the course of eighteen years, the Reilly group contributed substantially to the development of modern digital waveform technology (DWT), its implementation and characterization, methods of waveform generation, and general theory which includes but is not limited to stability diagrams, the pseudopotential model, and more recently digital quadrupole acceptance. In parallel to Reilly's achievements but also working separately, the Ding group at the Shimadzu Research Lab continued to implement their digital drive technology for a 3D ion trap. Finally, after 18 years Shimadzu unveiled a bench top MALDI square wave driven 3D ion trap mass spectrometer that was designed to work in the higher mass range at the 2019 ASMS conference. The DIT technology has also been developed and implemented in the linear and 3D quadrupole ion traps by many other groups around the world.
Sources: en.wikipedia.org
No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.
Naming for research peptides is not standardised, and suppliers sometimes apply the same label to different chain lengths. Certificates of analysis and mass data are the practical way to determine what a given lot contains.
The fragment commonly cited under this label is reported near 889 Da, and the parent protein near 4963 Da. Reported values shift with the exact sequence and with residual counter-ions or water in the sample.
Short transit at ambient temperature is generally tolerated, but long-term storage at room temperature is not recommended. Heat, moisture, and light all accelerate degradation. Cold, dry, dark storage is the conventional choice.